HTG2014-Section-Header-publications

Categories

Filter by Topics

AACR2023 ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling B-accute lyphoblastic seukemia B-ALL Biology of neoplasia Biomarkers Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN Blood bone Brain Breast Cancer CAR T cell therapy Cardiovascular Disease CDKN2A mutation Cell Free Plasma Cells Chemokines Circulating miRNAs clinical trial Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity Efficacy EHE cancer EMT Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER-2 HER2- HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins IOA- 244 IRP Kidney LAG3+ Liposarcoma Liquid Biopsy Liver liver liver tissue Lung lungs Lupus Lymphocytes lymphoma Lymphoma Melanoma melanoma Mesothelioma Microenvironment miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets OBP Oral cancer Oral Cancer oral squamous cell carcinoma OSCC Osteoarthritis palbociclib PALLET PALOMA PALOMA-2 PanB Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PDX model PENELOPE-B PFAS PI3K inhibitors PIK3CA mutation PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Rbsig Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma STAT6 pathway Sub-typing Testicular cancer Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Triple Negative Breast CancerTNBC Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2018

Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.

Finn, R. S., et al. Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. Abstract presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2018  Jun 2; Chicago, IL. 

View External Link

Targeted mRNA sequencing using small formalin-fixed, paraffin-embedded core biopsies to evaluate immune and tumor-associated gene expression in breast cancer

Sinn, B. V., et al Targeted mRNA sequencing using small formalin-fixed, paraffin embedded core biopsies to evaluate immune and tumor-associated gene expression in breast cancer. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany, Abstract #AG13.03

Download pdf 112KB

PQR309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy.

Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].

PMID: 29066507

View External Link

2017

Effective targeting of MYC expression with a novel nucleic acid binding (G4-quadruplex) small molecule coupled with HDAC inhibition synergizes to limit myeloma growth

Gaikwad, S. M., et al. Effective targeting of MYC expression with a novel nucleic acid binding (G4-quadruplex) small molecule coupled with HDAC inhibition synergizes to limit myeloma growth. Abstract presented at: American Association of Clinical Research (AACR) Annual meeting 2017; April 1-5, Washington, DC. DOI:10.1158/1538-7445.AM2017-194.

View External Link

Rabiopred, an innovative theragnostic tool for precision medicine in rheumatoid arthritis patients

Schordan, E., et al. Rabiopred, an innovative theragnostic tool for precision medicine in rheumatoid arthritis patients.  Abstract presented at Annual European congress of Rheumatology, 2017 JUN 14-17. Annals of the Rheumatic Diseases 2017 (76) S2:1463-1463. DOI: 10.1136/annrheumdis-2017-eular.6417

View External Link

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Sharma P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar 18(3):312

PMID: 28131785

View External Link

Page last updated May 22, 2023